Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes

BACKGROUND: Hepatocellular carcinoma (HCC) ranks as the sixth most common cancer and the second leading cause of cancer-related death worldwide, local and systemic therapies are beneficial for those who have more advanced disease or are not suitable for radical treatment. We aim to investigate the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yong, Tian, Huan, Xiang, Bin, Zhang, Yongjin, Liu, Jian, Cai, Zhuoyan, Xiang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376398/
https://www.ncbi.nlm.nih.gov/pubmed/34414963
http://dx.doi.org/10.1097/MD.0000000000026958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376398/
https://www.ncbi.nlm.nih.gov/pubmed/34414963
http://dx.doi.org/10.1097/MD.0000000000026958

Ejemplares similares